ALEC - Alector, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
ALEC price evolution
ALEC
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $49.09 | $74.1 | $76.1 | |
| Short term investments | $455.79 | $489.53 | $474.31 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $469.36 | $519.7 | $581.39 | $565.81 |
| Long term investments | ||||
| Property, plant & equipment | $39.02 | $43.37 | $45.16 | $47.06 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $51.03 | $54.1 | $56.02 | |
| Total investments | $455.79 | $489.53 | $474.31 | |
| Total assets | $516.02 | $570.73 | $635.49 | $621.83 |
| Current liabilities | ||||
| Accounts payable | $5.02 | $10.19 | $20.22 | $11.48 |
| Deferred revenue | $263.54 | $277.93 | $293.82 | |
| Short long term debt | $8.61 | $8.54 | $8.46 | |
| Total current liabilities | $142.53 | $147.68 | $164.92 | $177.95 |
| Long term debt | $27.51 | $29.02 | $30.46 | |
| Total noncurrent liabilities | $272.48 | $291.67 | $309.72 | |
| Total debt | $36.11 | $37.56 | $38.92 | |
| Total liabilities | $397.09 | $420.16 | $456.59 | $487.67 |
| Shareholders' equity | ||||
| Retained earnings | -$827.05 | -$784.83 | -$746.16 | -$710.08 |
| Other shareholder equity | $0.93 | -$0.62 | -$0.4 | $0.18 |
| Total shareholder equity | $150.57 | $178.91 | $134.16 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $76.1 | $155.79 | $330.62 | $51.44 |
| Short term investments | $474.31 | $558.53 | $406.1 | $363.34 |
| Net receivables | $2.59 | $7.39 | ||
| Inventory | ||||
| Total current assets | $565.81 | $726.43 | $749.71 | $421.51 |
| Long term investments | ||||
| Property, plant & equipment | $47.06 | $53.33 | $57.9 | $62.65 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $56.02 | $61.21 | $64.94 | $66.74 |
| Total investments | $474.31 | $558.53 | $406.1 | $363.34 |
| Total assets | $621.83 | $787.65 | $814.66 | $488.25 |
| Current liabilities | ||||
| Accounts payable | $11.48 | $4.19 | $4.75 | $3 |
| Deferred revenue | $293.82 | $491.6 | $425.22 | $132.3 |
| Short long term debt | $8.46 | $8.06 | $7.79 | $7.51 |
| Total current liabilities | $177.95 | $93.81 | $139.56 | $68.09 |
| Long term debt | $30.46 | $35.27 | $39.81 | $43.74 |
| Total noncurrent liabilities | $309.72 | $479.4 | $374.38 | $152.63 |
| Total debt | $38.92 | $43.33 | $47.6 | $51.26 |
| Total liabilities | $487.67 | $573.21 | $513.93 | $220.72 |
| Shareholders' equity | ||||
| Retained earnings | -$710.08 | -$579.69 | -$446.38 | -$410.05 |
| Other shareholder equity | $0.18 | -$4.58 | -$0.94 | $0.61 |
| Total shareholder equity | $134.16 | $214.44 | $300.72 | $267.53 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15.34 | $15.08 | $15.89 | $15.19 |
| Cost of revenue | ||||
| Gross Profit | $15.08 | $15.89 | $15.19 | |
| Operating activities | ||||
| Research & development | $46.31 | $45.17 | $47.72 | |
| Selling, general & administrative | $14.38 | $14.43 | $14.92 | |
| Total operating expenses | $61.58 | $60.69 | $59.6 | $62.64 |
| Operating income | -$45.61 | -$43.71 | -$47.45 | |
| Income from continuing operations | ||||
| EBIT | -$38.6 | -$36.07 | -$39.77 | |
| Income tax expense | $0.07 | $0.01 | $1.67 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$42.22 | -$38.68 | -$36.08 | -$41.43 |
| Income (for common shares) | -$38.68 | -$36.08 | -$41.43 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $97.06 | $133.62 | $207.09 | $21.1 |
| Cost of revenue | ||||
| Gross Profit | $97.06 | $133.62 | $207.09 | $21.1 |
| Operating activities | ||||
| Research & development | $192.12 | $210.42 | $189.41 | $156.87 |
| Selling, general & administrative | $56.69 | $61.03 | $55.04 | $59.4 |
| Total operating expenses | $248.8 | $271.45 | $244.44 | $216.27 |
| Operating income | -$151.74 | -$137.83 | -$37.36 | -$195.17 |
| Income from continuing operations | ||||
| EBIT | -$125.18 | -$130.06 | -$36.33 | -$190.23 |
| Income tax expense | $5.21 | $3.25 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$130.39 | -$133.31 | -$36.33 | -$190.23 |
| Income (for common shares) | -$130.39 | -$133.31 | -$36.33 | -$190.23 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$38.68 | -$36.08 | -$41.43 | |
| Operating activities | ||||
| Depreciation | $2.28 | $2.29 | $2.26 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.91 | $10.31 | $11.54 | |
| Total cash flows from operations | -$62.8 | -$61.35 | -$46.07 | |
| Investing activities | ||||
| Capital expenditures | -$0.34 | -$0.53 | -$0.23 | |
| Investments | $37.48 | -$11.23 | $18.3 | |
| Total cash flows from investing | $65.73 | $37.15 | -$11.77 | $18.07 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $71.11 | $1.47 | ||
| Net borrowings | ||||
| Total cash flows from financing | $71.75 | $0.64 | $71.11 | $0.59 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$37.4 | -$25.01 | -$2 | -$27.41 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$130.39 | -$133.31 | -$36.33 | -$190.23 |
| Operating activities | ||||
| Depreciation | $8.85 | $8.47 | $8.31 | $7.26 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $42.8 | $46.15 | $40.78 | $30.52 |
| Total cash flows from operations | -$184.16 | -$20.33 | $298.55 | -$166.73 |
| Investing activities | ||||
| Capital expenditures | -$2.38 | -$4.12 | -$3.25 | -$5.03 |
| Investments | $104.3 | -$154.9 | -$46.42 | -$100.02 |
| Total cash flows from investing | $101.92 | -$159.01 | -$49.66 | -$105.05 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.55 | $4.51 | $30.3 | $232.11 |
| Net borrowings | ||||
| Total cash flows from financing | $2.55 | $4.51 | $30.3 | $232.11 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$79.69 | -$174.83 | $279.18 | -$39.67 |
News
Fundamentals
| Market cap | $176.27M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 97.93M |
| Revenue | $61.51M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$158.41M |
| Revenue Q/Q | 68.43% |
| Revenue Y/Y | -36.14% |
| P/E ratio | -1.11 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.87 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.62 |
|---|---|
| ROA | -27.03% |
| ROE | N/A |
| Debt/Equity | 3.64 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.29 |
| Quick ratio | N/A |